Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19
Authors:
Open Access
- 29 December 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (12) , e2141328
Abstract
Respiratory complications leading to intubation or death occur in 25% of patients admitted to the hospital with COVID-19.1 Dexamethasone2 and tocilizumab3 have reduced mortality in hospitalized patients with severe COVID-19 pneumonia, whereas hydroxychloroquine, chloroquine, interferon, remdesivir, azithromycin, and convalescent plasma4-7 failed to do so.Keywords
This publication has 22 references indexed in Scilit:
- Colchicine in Patients with Chronic Coronary DiseaseNew England Journal of Medicine, 2020
- The COVID-19 pandemic: a catalyst to improve clinical trialsNature Reviews Cardiology, 2020
- Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019JAMA Network Open, 2020
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City AreaJAMA, 2020
- Cytokine release syndrome in severe COVID-19Science, 2020
- Efficacy and Safety of Low-Dose Colchicine after Myocardial InfarctionNew England Journal of Medicine, 2019
- Statistics in Medicine2016
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Why do we need some large, simple randomized trials?Statistics in Medicine, 1984